FDA approves targeted brain cancer drug from Jazz’s Chimerix buyout 

The FDA on Wednesday granted accelerated approval to Jazz Pharmaceuticals’ targeted glioma drug dordaviprone, marking the first treatment specifically for patients with a common subtype of the rare cancer. The treatment is for patients with ...